A novel phosphodiesterase 1 inhibitor reverses L-dopa-induced dyskinesia, but not motivation deficits, in monkeys

The enzyme phosphodiesterase 1 (PDE1) is highly expressed in the striatum and cortex. However, its role in corticostriatal function has not been fully investigated. The present study was aimed at evaluating the therapeutic potential of PDE1 inhibitors in treating motivation deficits and 3,4-dihydrox...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacology, biochemistry and behavior biochemistry and behavior, 2021-06, Vol.205, p.173183, Article 173183
Main Authors: Enomoto, Takeshi, Nakako, Tomokazu, Goda, Masao, Wada, Erika, Kitamura, Atsushi, Fujii, Yuki, Ikeda, Kazuhito
Format: Article
Language:English
Subjects:
L-Dopa-induced dyskinesia
Motivational deficits
Parkinsonian macaque model
Phosphodiesterase 1
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue
container_start_page 173183
container_title Pharmacology, biochemistry and behavior
container_volume 205
creator Enomoto, Takeshi
Nakako, Tomokazu
Goda, Masao
Wada, Erika
Kitamura, Atsushi
Fujii, Yuki
Ikeda, Kazuhito
description The enzyme phosphodiesterase 1 (PDE1) is highly expressed in the striatum and cortex. However, its role in corticostriatal function has not been fully investigated. The present study was aimed at evaluating the therapeutic potential of PDE1 inhibitors in treating motivation deficits and 3,4-dihydroxy-L-phenylalanine (L-dopa)-induced dyskinesia, which are pathological conditions of the corticostriatal system. We used a novel PDE1 inhibitor 3-ethyl-2-{[trans-4-(methoxymethyl)cyclohexyl]oxy}-7-(tetrahydro-2H-pyran-4-yl)-imidazo[5,1-f][1,2,4]triazin-4(3H)-one (DSR-143136), which was identified in our drug discovery program. Motivation in monkeys was measured using a progressive ratio task. L-Dopa-induced dyskinesia and disability scores were measured in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys. DSR-143136 had a high selectivity for PDE1 over other PDE families and 67 other biologic targets. A dopamine D1 receptor antagonist SCH-39166 at 0.01, 0.03 and 0.1 mg/kg potently decreased motivation in monkeys. However, DSR-143136 at 0.3 and 3 mg/kg did not affect motivation deficits induced by low-dose SCH-39166 (0.01 mg/kg). On the other hand, DSR-143136 at 3 mg/kg potently decreased L-dopa-induced dyskinesia in the Parkinsonian monkey model. Importantly, this antidyskinesic efficacy was NOT accompanied by detrimental effects on motor function. Further, this compound decreased on-time with marked or severe dyskinesia, without affecting on-time itself. These findings suggest that PDE1 inhibitor could be a therapeutic candidate for treating L-dopa-induced dyskinesia in Parkinson's disease, but not for motivation deficits. •The PDE1 inhibitor DSR-143136 decreases L-dopa-induced dyskinesia in monkeys.•DSR-143136 has no detrimental effects on motor function in monkeys.•DSR-143136 does not affect the dopamine D1 antagonist-induced motivation deficits.
doi_str_mv 10.1016/j.pbb.2021.173183
format article
fullrecord <record><control><sourceid>pubmed_elsev</sourceid><recordid>TN_cdi_pubmed_primary_33774006</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0091305721000824</els_id><sourcerecordid>33774006</sourcerecordid><originalsourceid>FETCH-LOGICAL-e230t-8dc36475dd33d6957f5a64e5120ed358ce53c036cc90b580b427f57c20931f1b3</originalsourceid><addsrcrecordid>eNo1kMtqwzAQRUVpadK0H9BN0QfU7siyLIeuQugLAt20a2FJY6I8bFdSDPn7KqRdDAPD4TL3EHLPIGfAqqdNPmidF1CwnEnOan5BpqyWPBNMyksyBZizjIOQE3ITwgYAyqKS12TCuZQlQDUlPwva9SPu6LDuQxrrMET0TUDKqOvWTrvYe-pxRB8w0FVm-6HJXGcPBi21x7B1HQbXPFJ9iCkr0n0f3dhE13fUYuuMi-ExRaV7t8VjuCVXbbMLePe3Z-T79eVr-Z6tPt8-lotVhgWHmNXW8KqUwlrObTUXshVNVaJgBaDlojYouAFeGTMHLWrQZZEQaQqYc9YyzWfk4Zw7HPQerRq82zf-qP67J-D5DGD6YnToVTAOu1TLeTRR2d4pBupkWm1UMq1OptXZNP8FQmZxYQ</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A novel phosphodiesterase 1 inhibitor reverses L-dopa-induced dyskinesia, but not motivation deficits, in monkeys</title><source>Elsevier</source><creator>Enomoto, Takeshi ; Nakako, Tomokazu ; Goda, Masao ; Wada, Erika ; Kitamura, Atsushi ; Fujii, Yuki ; Ikeda, Kazuhito</creator><creatorcontrib>Enomoto, Takeshi ; Nakako, Tomokazu ; Goda, Masao ; Wada, Erika ; Kitamura, Atsushi ; Fujii, Yuki ; Ikeda, Kazuhito</creatorcontrib><description>The enzyme phosphodiesterase 1 (PDE1) is highly expressed in the striatum and cortex. However, its role in corticostriatal function has not been fully investigated. The present study was aimed at evaluating the therapeutic potential of PDE1 inhibitors in treating motivation deficits and 3,4-dihydroxy-L-phenylalanine (L-dopa)-induced dyskinesia, which are pathological conditions of the corticostriatal system. We used a novel PDE1 inhibitor 3-ethyl-2-{[trans-4-(methoxymethyl)cyclohexyl]oxy}-7-(tetrahydro-2H-pyran-4-yl)-imidazo[5,1-f][1,2,4]triazin-4(3H)-one (DSR-143136), which was identified in our drug discovery program. Motivation in monkeys was measured using a progressive ratio task. L-Dopa-induced dyskinesia and disability scores were measured in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys. DSR-143136 had a high selectivity for PDE1 over other PDE families and 67 other biologic targets. A dopamine D1 receptor antagonist SCH-39166 at 0.01, 0.03 and 0.1 mg/kg potently decreased motivation in monkeys. However, DSR-143136 at 0.3 and 3 mg/kg did not affect motivation deficits induced by low-dose SCH-39166 (0.01 mg/kg). On the other hand, DSR-143136 at 3 mg/kg potently decreased L-dopa-induced dyskinesia in the Parkinsonian monkey model. Importantly, this antidyskinesic efficacy was NOT accompanied by detrimental effects on motor function. Further, this compound decreased on-time with marked or severe dyskinesia, without affecting on-time itself. These findings suggest that PDE1 inhibitor could be a therapeutic candidate for treating L-dopa-induced dyskinesia in Parkinson's disease, but not for motivation deficits. •The PDE1 inhibitor DSR-143136 decreases L-dopa-induced dyskinesia in monkeys.•DSR-143136 has no detrimental effects on motor function in monkeys.•DSR-143136 does not affect the dopamine D1 antagonist-induced motivation deficits.</description><identifier>ISSN: 0091-3057</identifier><identifier>EISSN: 1873-5177</identifier><identifier>DOI: 10.1016/j.pbb.2021.173183</identifier><identifier>PMID: 33774006</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>L-Dopa-induced dyskinesia ; Motivational deficits ; Parkinsonian macaque model ; Phosphodiesterase 1</subject><ispartof>Pharmacology, biochemistry and behavior, 2021-06, Vol.205, p.173183, Article 173183</ispartof><rights>2021 Elsevier Inc.</rights><rights>Copyright © 2021 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,783,787,27936,27937</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33774006$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Enomoto, Takeshi</creatorcontrib><creatorcontrib>Nakako, Tomokazu</creatorcontrib><creatorcontrib>Goda, Masao</creatorcontrib><creatorcontrib>Wada, Erika</creatorcontrib><creatorcontrib>Kitamura, Atsushi</creatorcontrib><creatorcontrib>Fujii, Yuki</creatorcontrib><creatorcontrib>Ikeda, Kazuhito</creatorcontrib><title>A novel phosphodiesterase 1 inhibitor reverses L-dopa-induced dyskinesia, but not motivation deficits, in monkeys</title><title>Pharmacology, biochemistry and behavior</title><addtitle>Pharmacol Biochem Behav</addtitle><description>The enzyme phosphodiesterase 1 (PDE1) is highly expressed in the striatum and cortex. However, its role in corticostriatal function has not been fully investigated. The present study was aimed at evaluating the therapeutic potential of PDE1 inhibitors in treating motivation deficits and 3,4-dihydroxy-L-phenylalanine (L-dopa)-induced dyskinesia, which are pathological conditions of the corticostriatal system. We used a novel PDE1 inhibitor 3-ethyl-2-{[trans-4-(methoxymethyl)cyclohexyl]oxy}-7-(tetrahydro-2H-pyran-4-yl)-imidazo[5,1-f][1,2,4]triazin-4(3H)-one (DSR-143136), which was identified in our drug discovery program. Motivation in monkeys was measured using a progressive ratio task. L-Dopa-induced dyskinesia and disability scores were measured in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys. DSR-143136 had a high selectivity for PDE1 over other PDE families and 67 other biologic targets. A dopamine D1 receptor antagonist SCH-39166 at 0.01, 0.03 and 0.1 mg/kg potently decreased motivation in monkeys. However, DSR-143136 at 0.3 and 3 mg/kg did not affect motivation deficits induced by low-dose SCH-39166 (0.01 mg/kg). On the other hand, DSR-143136 at 3 mg/kg potently decreased L-dopa-induced dyskinesia in the Parkinsonian monkey model. Importantly, this antidyskinesic efficacy was NOT accompanied by detrimental effects on motor function. Further, this compound decreased on-time with marked or severe dyskinesia, without affecting on-time itself. These findings suggest that PDE1 inhibitor could be a therapeutic candidate for treating L-dopa-induced dyskinesia in Parkinson's disease, but not for motivation deficits. •The PDE1 inhibitor DSR-143136 decreases L-dopa-induced dyskinesia in monkeys.•DSR-143136 has no detrimental effects on motor function in monkeys.•DSR-143136 does not affect the dopamine D1 antagonist-induced motivation deficits.</description><subject>L-Dopa-induced dyskinesia</subject><subject>Motivational deficits</subject><subject>Parkinsonian macaque model</subject><subject>Phosphodiesterase 1</subject><issn>0091-3057</issn><issn>1873-5177</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNo1kMtqwzAQRUVpadK0H9BN0QfU7siyLIeuQugLAt20a2FJY6I8bFdSDPn7KqRdDAPD4TL3EHLPIGfAqqdNPmidF1CwnEnOan5BpqyWPBNMyksyBZizjIOQE3ITwgYAyqKS12TCuZQlQDUlPwva9SPu6LDuQxrrMET0TUDKqOvWTrvYe-pxRB8w0FVm-6HJXGcPBi21x7B1HQbXPFJ9iCkr0n0f3dhE13fUYuuMi-ExRaV7t8VjuCVXbbMLePe3Z-T79eVr-Z6tPt8-lotVhgWHmNXW8KqUwlrObTUXshVNVaJgBaDlojYouAFeGTMHLWrQZZEQaQqYc9YyzWfk4Zw7HPQerRq82zf-qP67J-D5DGD6YnToVTAOu1TLeTRR2d4pBupkWm1UMq1OptXZNP8FQmZxYQ</recordid><startdate>20210601</startdate><enddate>20210601</enddate><creator>Enomoto, Takeshi</creator><creator>Nakako, Tomokazu</creator><creator>Goda, Masao</creator><creator>Wada, Erika</creator><creator>Kitamura, Atsushi</creator><creator>Fujii, Yuki</creator><creator>Ikeda, Kazuhito</creator><general>Elsevier Inc</general><scope>NPM</scope></search><sort><creationdate>20210601</creationdate><title>A novel phosphodiesterase 1 inhibitor reverses L-dopa-induced dyskinesia, but not motivation deficits, in monkeys</title><author>Enomoto, Takeshi ; Nakako, Tomokazu ; Goda, Masao ; Wada, Erika ; Kitamura, Atsushi ; Fujii, Yuki ; Ikeda, Kazuhito</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e230t-8dc36475dd33d6957f5a64e5120ed358ce53c036cc90b580b427f57c20931f1b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>L-Dopa-induced dyskinesia</topic><topic>Motivational deficits</topic><topic>Parkinsonian macaque model</topic><topic>Phosphodiesterase 1</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Enomoto, Takeshi</creatorcontrib><creatorcontrib>Nakako, Tomokazu</creatorcontrib><creatorcontrib>Goda, Masao</creatorcontrib><creatorcontrib>Wada, Erika</creatorcontrib><creatorcontrib>Kitamura, Atsushi</creatorcontrib><creatorcontrib>Fujii, Yuki</creatorcontrib><creatorcontrib>Ikeda, Kazuhito</creatorcontrib><collection>PubMed</collection><jtitle>Pharmacology, biochemistry and behavior</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Enomoto, Takeshi</au><au>Nakako, Tomokazu</au><au>Goda, Masao</au><au>Wada, Erika</au><au>Kitamura, Atsushi</au><au>Fujii, Yuki</au><au>Ikeda, Kazuhito</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A novel phosphodiesterase 1 inhibitor reverses L-dopa-induced dyskinesia, but not motivation deficits, in monkeys</atitle><jtitle>Pharmacology, biochemistry and behavior</jtitle><addtitle>Pharmacol Biochem Behav</addtitle><date>2021-06-01</date><risdate>2021</risdate><volume>205</volume><spage>173183</spage><pages>173183-</pages><artnum>173183</artnum><issn>0091-3057</issn><eissn>1873-5177</eissn><abstract>The enzyme phosphodiesterase 1 (PDE1) is highly expressed in the striatum and cortex. However, its role in corticostriatal function has not been fully investigated. The present study was aimed at evaluating the therapeutic potential of PDE1 inhibitors in treating motivation deficits and 3,4-dihydroxy-L-phenylalanine (L-dopa)-induced dyskinesia, which are pathological conditions of the corticostriatal system. We used a novel PDE1 inhibitor 3-ethyl-2-{[trans-4-(methoxymethyl)cyclohexyl]oxy}-7-(tetrahydro-2H-pyran-4-yl)-imidazo[5,1-f][1,2,4]triazin-4(3H)-one (DSR-143136), which was identified in our drug discovery program. Motivation in monkeys was measured using a progressive ratio task. L-Dopa-induced dyskinesia and disability scores were measured in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys. DSR-143136 had a high selectivity for PDE1 over other PDE families and 67 other biologic targets. A dopamine D1 receptor antagonist SCH-39166 at 0.01, 0.03 and 0.1 mg/kg potently decreased motivation in monkeys. However, DSR-143136 at 0.3 and 3 mg/kg did not affect motivation deficits induced by low-dose SCH-39166 (0.01 mg/kg). On the other hand, DSR-143136 at 3 mg/kg potently decreased L-dopa-induced dyskinesia in the Parkinsonian monkey model. Importantly, this antidyskinesic efficacy was NOT accompanied by detrimental effects on motor function. Further, this compound decreased on-time with marked or severe dyskinesia, without affecting on-time itself. These findings suggest that PDE1 inhibitor could be a therapeutic candidate for treating L-dopa-induced dyskinesia in Parkinson's disease, but not for motivation deficits. •The PDE1 inhibitor DSR-143136 decreases L-dopa-induced dyskinesia in monkeys.•DSR-143136 has no detrimental effects on motor function in monkeys.•DSR-143136 does not affect the dopamine D1 antagonist-induced motivation deficits.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>33774006</pmid><doi>10.1016/j.pbb.2021.173183</doi></addata></record>
fulltext fulltext
identifier ISSN: 0091-3057
ispartof Pharmacology, biochemistry and behavior, 2021-06, Vol.205, p.173183, Article 173183
issn 0091-3057
1873-5177
language eng
recordid cdi_pubmed_primary_33774006
source Elsevier
subjects L-Dopa-induced dyskinesia
Motivational deficits
Parkinsonian macaque model
Phosphodiesterase 1
title A novel phosphodiesterase 1 inhibitor reverses L-dopa-induced dyskinesia, but not motivation deficits, in monkeys
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-18T00%3A15%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_elsev&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20novel%20phosphodiesterase%201%20inhibitor%20reverses%20L-dopa-induced%20dyskinesia,%20but%20not%20motivation%20deficits,%20in%20monkeys&rft.jtitle=Pharmacology,%20biochemistry%20and%20behavior&rft.au=Enomoto,%20Takeshi&rft.date=2021-06-01&rft.volume=205&rft.spage=173183&rft.pages=173183-&rft.artnum=173183&rft.issn=0091-3057&rft.eissn=1873-5177&rft_id=info:doi/10.1016/j.pbb.2021.173183&rft_dat=%3Cpubmed_elsev%3E33774006%3C/pubmed_elsev%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-e230t-8dc36475dd33d6957f5a64e5120ed358ce53c036cc90b580b427f57c20931f1b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/33774006&rfr_iscdi=true